leqembi news - Search News

Seeking Alpha on MSN · 7h

Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s Alzheimer’s drug Leqembi. The investment bank said it doesn’t expect Biogen (BIIB) to return to growth until 2026,

Business Insider · 8h

Needham downgrades Biogen to Hold on lack of share catalysts

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares

ca.investing.com on MSN · 6h

Needham downgrades Biogen on slow growth of Alzheimer's drug

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months. The brokerage stated that Leqembi’s sales

Worldcrunch on MSN7h

Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

6h

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

Leqembi Okayed for Subset of Early Alzheimer’s Patients

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

GlobalData on MSN4d

EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

3d

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

EU Gives Green Light: Leqembi on the Verge of Alzheimer's Approval

The EU's drugs regulator recommends approval of Eisai and Biogen's Alzheimer's drug, Leqembi, for patients with early stages ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results